References
- Cancer in Slovenia 2015 Ljubljana: Institute of Oncology Ljubljana, Epidemiology and Cancer Registry, Cancer Registry of republic of Slovenia; 2018.
- Schmoll1 HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, et al. ESMO consensus guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol 2012; 23: 2479-516. doi: 10.1093/annonc/mds236
- Van Cutsem1 E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, et al ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 2016; 1386-422. doi: 10.1093/annonc/mdw235
- National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: colon cancer. V.2.2018. [cited 2018 Jun 15]. Available at: http://www.nccn.org/profesionals/phisician_gls/PDF/colon.pdf
- National Comprehensive Cancer Network: NCCN clinical practice guidelines in oncology: rectal cancer. V.2.2018 [cited 2018 Aug 3]. Available at: http://www.nccn.org/profesionals/phisician_gls/PDF/colon.pdf
- Biagi JJ, Raphael MJ, Mackillop WJ, Kong W, King WD, Booth CM. Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer. A systemic review and meta-analysis. JAMA 2011; 305: 233542. doi: 10.1001/jama.2011.749
- Ocvirk J. Advances in the treatment of metastatic colorectal carcinoma. Radiol Oncol 2009; 43: 1-8. doi: 10.2478/v10019-009-0004-1
- Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl Med 2005; 352: 476-87. doi: 10.1053/j.gastro.2008.02.098
- Esin E, Yalcin S. Maintenance strategy in metastatic colorectal cancer: a systematic review. Cancer Treat Rev 2016; 42: 82-90. doi: 10.1016/j. ctrv.2015.10.012
- Advanced colorectal cancer: ESMO clinical practice guidelines for diagnosis, treatment. Ann Oncol 2010; 21: v93- 7. doi: 10.1093/annonc/mdq222
- Markowitz SD, Bertagnolli MM. Molecular basis of colorectal cancer. N Engl J Med 2009; 361: 2449-60. doi: 10.1056/NEJMra0804588
- De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, Lamba S, et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 2010; 304: 1812- 20. doi: 10.1001/jama.2010.1535
- De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, et al. Effect of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010; 11: 753-62. doi: 10.1016/S1470-2045(10)70130-3
- Tol J, Nagtegaal ID, Punt CJA. BRAF mutation in metastatic colorectal cancer. N Engl J Med 2009; 361: 98-99. doi: 10.3978/j.issn.2078-6891.2015.077
- Samowitz WS, Sweeney C, Herrick J, Albertsen H, Levin TR, Murtaugh MA, et al. Poor survival associated with the BRAF V600E mutation in microsatellite- stable colon cancer. Caner Res 2005; 65: 6063-9. doi: 10.1158/0008-5472.CAN-05-0404
- Ličar A, Cerkovnik P, Novaković S. Distribution of some activating KRAS and BRAF mutations in Slovene patients with colorectal cancer. Med Oncol 2011; 28: 1048-53. doi: 10.1007/s12032-010-9631-z
- Fariña-Sarasqueta A, van Lijnschoten G, Moerland E, Creemers GJ, Lemmens VE, Rutten HJ, et al. The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients. Ann Oncol 2010; 21: 2396-402. doi: 10.1093/annonc/mdq258
- Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-47. doi: 10.1016/j.ejca.2008.10.026
- Marzouk O, Schofield J. Review of histopathological and molecular prognostic features in colorectal cancer. Cancers 2011; 3: 276-81. doi: 10.3390/cancers3022767
- Ličar A, Cerkovnik P, Ocvirk J, Novaković S. KRAS mutations in Slovene patients with colorectal cancer: frequency, distribution and correlation with the response to treatment. Int J Oncol 2010; 36: 1137-44. doi: 10.3892/ijo_00000596.
- Artale S, Sartore- Bianchi A, Veronese SM, Gambi V, Sarnataro CS, Gambacorta M, et al. Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol 2008; 26: 4217- 9. doi: 10.1200/JCO.2008.18.7266
- Bokemeyer C, Van Cutsem E, Rougier P, Ciardiello F, Heeger S, Schlichting M, et al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer 2012; 48: 146675. doi: 10.1016/j.ejca.2012.02.057
- Artale S, Sartore- Bianchi A, Veronese SM, Gambi V, Sarnataro CS, Gambacorta M, et al. Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol 2008; 26: 4217-9. doi: 10.1200/JCO.2008.18.7286
- Rebersek M, Boc M, Škerl P, Benedik J, Hlebanja Z, Volk N, et al. Efficacy of first- line systemic treatment in correlation with BRAF V600E and different KRAS mutations colorectal cancer - a single institution retrospective analysis. Radiol Oncol 2011; 45: 285-91. doi: 10.2478/v10019-011-0039-y
- Lambrechts D, De Roock W, Prenen H, De Schutter J, Jacobs B, Biesmans B, et al. The role of KRAS, BRAF, NRAS and PIK3CA mutations as a markers of resistance of cetuximab in chemorefractory metastatic colorectal cancer. J Clin Oncol 2009; 27: 9020. doi: 10.1158/1078-0432.CCR-08-2961
- Tejpar S, De Roock W. PIK3CA, BRAF and KRAS mutations and outcome prediction in chemorefractory metastatic colorectal cancer (mCRC) patients treated With EGFR targeting monoclonal antibodies (MoAbs): results of a European Consortium[abstract]. Eur J Cancer Suppl 2009; 7: 322. No. 6005
- Loupakis F, Ruzzo A, Cremolini C, Vincenzi B, Salvatore L, Santini D, et al. KRAS codon 61, 146 and BRAF mutations predict resistence to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer 2009; 101: 715-21. doi: 10.18632/oncotarget.13697
- Tejpar S, Celik I, Schlichting M, Sartorius U, Bokemeyer C, Van Cutsem E. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J Clin Oncol 2012; 30: 3570-7. doi: 10.1200/JCO.2012.42.2592
- Peeters M, Douillard JY, Van Cutsem E, Siena S, Zhang K, Williams R, et al. Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab. J Clin Oncol 2013; 31: 759-65. doi: 10.1200/JCO.2012.45.1492. Epub 2012 Nov 26.
- Roth AD, Tejpar S, Dolorenzi M, Yan P, Fiocca R, Klingbiel D, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010: 28: 466-74. doi: 10.1200/JCO.2009.23.3452.
- Fujiyoshi K, Yamamoto G, Takahashi A, Arai Y, Yamada M, Kakuta M, et al. High concordance rate of KRAS/BRAF mutations and MSI-H between primary colorectal cancer and corresponding metastases. Oncol Rep 2017; 37: 785-92. doi: 10.3892/or.2016.5323.
- Gaedcke J, Grade M, Jung K, Schirmer M, Jo P, Obermeyer C, et al. KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy. Radiother Oncol 2010; 94: 76-81. doi: 10.1016/j. radonc.2009.10.001
- Pietrantonio F, Cremolini C, Petrelli F, Di Bartolomeo M, Loupakis F, Maggi C, et al. First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. Crit Rev Oncol Hematol 2015; 96: 156-66. doi: 10.1016/j.critrevonc.2015.05.016
- Sorich MJ, Wiese MD, Rowland A, Kichenadasse G, McKinnon RA, Karapetis CS, et al. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. Ann Oncol 2015; 26: 13-21. doi: 10.1093/annonc/mdu378
- Scartozzi M, Galizia E, Chiorrini S, Giampieri G, Berardi R, Pieratoni C, et al. Arterial hypertension correlates with clinical outcome in colorectal cancer treated with first- line bevacizumab. Clin Oncol 2009; 20: 227-30. doi: 10.1093/annonc/mdn637
- Mir O, Ropert S, Alexandre J, Goldwasser F. Hypertension as a surrogate marker for the activity of anti- VEGF agents. Ann Oncol 2009; 20: 967-70. doi: 10.1093/annonc/mdp206
- Poole C, Gardiner J, Twelves C, Johnston P, Harper P, Cassidy J, et al. Effect of renal impairment on the pharmacokinetics and tolarebility of capecitabine (Xeloda) in cancer patients. Cancer Chemother Pharmacol 2002; 49: 225-34. doi: 10.1007/s00280-001-4808-0
- Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, Boyer M, et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 2002; 13: 566-75. doi: 10.1200/JCO.2001.19.21.4097
- Hoskins JM, Goldberg RM, Qu P, Ibrahim JG, McLeod HL. UGT1A1* 28 genotype and irinotecan- induced neutropenia: dose matters. J Nati Cancer Inst 2007; 99: 1290-421. doi: 10.1200/JCO.2009.21.7943
- Hoskins JM, McLeod HL. UGT1A and irinotecan toxicity: keeping it in the family. J Clin Oncol 2009; 27: 2419-21. doi: 10.2217/pgs.10.95
- Pereg D, Lishner M. Bevacizumab treatment for cancer treatment with cardiovascular disease: a double edged sword? Eur Heart J 2008; 29: 2325-26. doi: 10.1093/eurheartj/ehn384.
- Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F, et al. Arterial thromboembolic events in patients with metastatic colorectal cancer treated with chemotherapy and bevacizumab. J Nati Cancer Inst 2007; 1232-9. 0.1093/jnci/djm086
- Lee CS, Ryan EJ, Glen A Doherty GA. Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation. World J Gastroenterol 2014; 20: 3751-61. doi: 10.3748/wjg.v20.i14.3751
- Ocvirk J, Rebersek M. Management of cutaneous side effect of cetuximab therapy with K1 creme. Radiol Oncol 2008; 42: 215-24. doi: 10.2478/v10019-008-0022-4
- Ocvirk J, Cencelj S. Management of cutaneous side-effect of cetuximab therapy in patients with metastatic colorectal cancer. JEADV 2010; 24: 4539. doi: 10.1111/j.1468-3083.2009.03446.x
- Ocvirk J, Rebersek M, Boc M, Mesti T, Ebert Moltara M. Prophylactic use of K1 crem for reducing skin toxicity during cetuximab treatment in patients with metastatic colorectal cancer (mCRC). J Clin Oncol 2016; 28(15 Suppl): V124. doi: 10.1200/jco.2010.28.15_suppl.e14011.
- Siena S, Glynne-Jones R, Adenis A, Thaler J, Preusser P, Aguilar EA, et al. Reduced incidence of infusion- related reactions in metastatic colorectal cancer during treatment with cetuximab plus irinotecan with combined corticosteroid and antihistamin premedication. Cancer 2010, 116: 1827-37. doi: 10.1002/cncr.24945
- Venderbosch, ID Nagtegaal, TS Maughan, CG Smith , JP Cheadle, D Fisher, et al. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Clin Cancer Res 2014 20: 5322-30. doi: 10.1158/1078-0432. CCR-14-0332
- Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015; 372: 2509-20. doi: 10.1056/NEJMoa1500596
- Therkildsen C, Bergmann TK, Henrichsen-Schnack T, Ladelund S, Nilbert M. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: a systematic review and meta-analysis. Acta Oncol 2014; 53: 852-64. doi: 10.3109/0284186X.201 4.895036